Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537479 | 1.00 | TSHR (0.48) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14417018 | 1.00 | TSHR (0.48) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4282581 | 0.87 | TSHR (0.54) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8402568 | 0.86 | PDE4A (0.46) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Ethylene SCHEMBL6410194 | 0.84 | TSHR (0.51) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14448350 | 0.82 | MAPK1 (0.53) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6410186 | 0.81 | TSHR (0.47) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3247280 | 0.80 | CYP3A4 (0.49) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8090166 | 0.79 | TSHR (0.48) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8323174 | 0.79 | SMPD1 (0.48) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968953-A2 | METHOD FOR ISOLATING (R)-TOFISOPAM | Vela Acquisition Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| US-7265106-B2 | Method for isolating (R)-tofisopam | VELA AQUISITION CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| WO-2007078808-A2 | METHOD FOR ISOLATING (R)-TOFISOPAM | VELA ACQUISITION CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20060128955-A1 | Method of isolating (R)-tofisopam | VELA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | US | disclosed |
| US-20040254174-A1 | Method for isolating (R)-tofisopam | VELA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | US | disclosed |
| US-RE30014-E | 1-(3,4-Dimethoxy-phenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine | Egyesult Gyogyazer-es Tapozergyar (HU) | 1979-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254174-A1 | Method for isolating (R)-tofisopam | AMY1A, SI, IRS1 | TSHR 2638/4885CYP1A2 2813/4885CYP3A4 2513/4885 |
| US-20060128955-A1 | Method of isolating (R)-tofisopam | NPEPPS, NPPA, THOP1 | TSHR 838/4885CYP1A2 1048/4885CYP3A4 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.